Director & 10% Owner Akkaraju Srinivas Reports $5M Stock Purchase
KLRS has more than doubled off its 52-week low of $2.14.
Summary
Director and 10% owner Akkaraju Srinivas, through Samsara Opportunity Fund, L.P., reported a significant $5 million open market purchase of Kalaris Therapeutics common stock, signaling strong insider confidence.
Key Events · Ownership and Investor Activity · KLRS
-
Substantial Insider Investment
Director and 10% owner Akkaraju Srinivas, through Samsara Opportunity Fund, L.P., acquired $5,000,006 worth of Kalaris Therapeutics common stock.
-
Purchase at Premium
The shares were purchased at $10.42 per share on December 18, 2025, which is above the current market price of $8.265.
-
Increased Indirect Holdings
This transaction significantly increased the reporting person's indirect beneficial ownership to 1,979,847 shares.
-
Amended Disclosure
The filing serves as an amendment to a prior Form 4 filed on December 22, 2025, providing updated details on the December 18, 2025, purchase.
Analysis · KLRS · Life Sciences
This Form 4 filing reveals a substantial $5,000,006 open market purchase of Kalaris Therapeutics common stock by Director and 10% owner Akkaraju Srinivas, executed indirectly through Samsara Opportunity Fund, L.P. This significant investment, made at a price of $10.42 per share compared to the current stock price of $8.265, demonstrates strong conviction from a key insider despite the shares being acquired at a premium to today's market. The transaction, which occurred on December 18, 2025, and is reported as an amendment to a prior filing, represents a material vote of confidence in the company's future. This purchase likely contributes to the updated ownership information expected in the concurrently filed Schedule 13D/A. Investors should consider this a highly positive signal, indicating that a major stakeholder sees significant value in the company.
At the time of this filing, KLRS was trading at $8.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $138.3M. The 52-week trading range was $2.14 to $12.90. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.